The research on hepatitis D should be taken seriously
10.3969/j.issn.1001-5256.2023.04.001
- VernacularTitle:重视丁型肝炎研究
- Author:
Hui ZHUANG
1
Author Information
1. Department of Microbiology and Infectious Disease Center, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China
- Publication Type:Editorial
- Keywords:
Hepatitis D;
Virology;
Epidemiology;
Signs and Symptoms;
Drug Therapy
- From:
Journal of Clinical Hepatology
2023;39(4):737-741
- CountryChina
- Language:Chinese
-
Abstract:
Hepatitis D virus (HDV) infection is an important health problem around the world. The epidemiology of HDV infection has been changed significantly over the past 10 years due to widespread hepatitis B vaccination and human migration. HDV infection can manifest as co-infection or superinfection. Patients with HBV/HDV co-infection have a significantly higher risk of liver cirrhosis and hepatocellular carcinoma than those with HBV infection alone. Research and development are being conducted for new therapeutic drugs for hepatitis D, some of which have entered phase Ⅲ clinical trials. These drugs will replace the current therapies with lower efficacy.
